← Back to Search

Stress Kinase Inhibitor

MW150 for Alzheimer's Disease (SKI-AD Trial)

Phase 2
Waitlist Available
Led By Lawrence S Honig, MD PhD
Research Sponsored by Neurokine Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female, age 50 to 90 inclusive
Meet criteria for Alzheimer's Disease by NIAA-AA criteria
Must not have
Presence of clinically significant disorders of the central nervous system other than Alzheimer's disease, such as Lewy Body Disease, Parkinson's disease, hydrocephalus, epilepsy, demyelinating disease, brain tumors, or psychiatric disorders (such as schizophrenia, or severe affective disorders)
Serious or unstable hematologic, hepatic, renal, pulmonary, cardiac, or other medical disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 84 days treatment
Awards & highlights

Summary

This trial is testing a new pill called MW150 for people with mild-to-moderate Alzheimer's disease. The pill works by blocking a brain protein that may cause Alzheimer's symptoms. The study aims to see if the pill is safe and if it helps improve memory and daily activities.

Who is the study for?
This trial is for men and women aged 50-90 with mild-to-moderate Alzheimer's Disease, who have a study partner and can speak English fluently. Participants must not have significant other medical conditions or psychiatric disorders, no recent drug/alcohol abuse, and if female, be non-childbearing. Males must agree to use contraception.
What is being tested?
The trial tests MW150, an oral drug believed to affect stress kinases involved in Alzheimer's. It compares the effects of MW150 against a placebo on safety, how the body processes it, cognitive performance, daily activities behavior and blood biomarkers.
What are the potential side effects?
Specific side effects are not listed but will include monitoring for any adverse reactions related to the investigational drug MW150 as compared to a placebo. Safety assessments will focus on tolerability and potential impacts on liver function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 90 years old.
Select...
I have been diagnosed with Alzheimer's Disease.
Select...
I have someone who can come with me to appointments and sees me often.
Select...
I am a woman who cannot become pregnant because I am postmenopausal or have been surgically sterilized.
Select...
I can hear and see well enough for daily activities.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have central nervous system disorders other than Alzheimer's.
Select...
I do not have any serious or unstable health conditions.
Select...
I do not have major brain abnormalities like hydrocephalus or brain tumors.
Select...
I have chronic hepatitis B or C.
Select...
I have an immune disorder treated with immunosuppressants in the last year.
Select...
I have been diagnosed with HIV.
Select...
I have had COVID-19 or another viral infection in the last 3 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~84 days treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 84 days treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Drug Safety- Blood tests
Drug Safety- C-SSRS
Drug Safety- Electrocardiographic
+1 more
Secondary study objectives
Behavioral Scale - NPI-Q
Cognitive change-ADAScog
Cognitive change-Executive
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 10mg MW150 dailyExperimental Treatment1 Intervention
10 mg MW150 daily (1 capsule of 10 mg daily)
Group II: placebo dailyPlacebo Group1 Intervention
placebo daily (1 capsule of matched placebo daily)

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Alzheimer's Disease include cholinesterase inhibitors (e.g., donepezil, rivastigmine) and NMDA receptor antagonists (e.g., memantine). Cholinesterase inhibitors work by preventing the breakdown of acetylcholine, a neurotransmitter important for learning and memory, thereby enhancing cholinergic function. NMDA receptor antagonists help regulate glutamate activity to prevent excitotoxicity, which can damage neurons. These treatments are symptomatic and aim to improve cognitive function and slow disease progression. The investigational drug MW150, a p38alphaMAPK kinase inhibitor, targets neuroinflammation by inhibiting a specific stress kinase pathway involved in inflammatory responses. This approach is significant as neuroinflammation is a key factor in Alzheimer's pathogenesis, and reducing it may help protect neurons and improve clinical outcomes.

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,751 Previous Clinical Trials
28,123,791 Total Patients Enrolled
Neurokine TherapeuticsLead Sponsor
Columbia UniversityOTHER
1,480 Previous Clinical Trials
2,621,834 Total Patients Enrolled

Media Library

MW150 (Stress Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05194163 — Phase 2
Alzheimer's Disease Research Study Groups: 10mg MW150 daily, placebo daily
Alzheimer's Disease Clinical Trial 2023: MW150 Highlights & Side Effects. Trial Name: NCT05194163 — Phase 2
MW150 (Stress Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05194163 — Phase 2
~7 spots leftby Oct 2025